0,1,2,3,4,5,6
Table 6.4.3: Key findings - Hormonal treatment combined with chemotherapy,,,,,,
,"STAMPEDE [849, 1135]",,GETUG-AFU 15 [1134],,"CHAARTED [1112,1113]",
,ADT,ADT + Docetaxel    (6 cycles) + P,ADT,ADT + Docetaxel    (9 cycles),ADT,ADT + Docetaxel    (6 cycles)
N,"1,184",592,193,192,393,397
Newly   diagnosed M+,58%,59%,75%,67%,73%,73%
Key inclusion   criteria,"Patients scheduled for long-  term ADT  -  newly diagnosed M1 or N+   situations  -  locally advanced (at least two   of cT3 cT4, ISUP grade > 4,   PSA > 40 ng/mL)  -  relapsing locally treated   disease with a PSA > 4 ng/mL   and a PSA-DT < 6 mo.   or PSA > 20 ng/mL,  or nodal  or metastatic relapse",Metastatic disease   Karnofsky score > 70%,"Metastatic disease    ECOG PS 0, 1 or 2",,,
Primary   objective,OS,OS,OS,,,
Median follow   up (mo),43; 78.2 (update M1),50,54 (update),,,
HR (95% CI),0.78 (0.66-0.93),1.01 (0.75-1.36),0.72 (0.59-0.89),,,
M1 only,,,,,,
"N  1,086  -  -",,,,,,
HR (95% CI)  0.81 (0.69-0.95)  -  -,,,,,,
